Clinical Trial

French National Cohort of Patients With PRSS1 Mutations

Study acronym: PARADISIO 1
Recruiting
View on ClinicalTrials.gov →
Summary
The diagnosis of hereditary pancreatitis (PH) is based on a genetic criterion - detection of a mutation in the PRSS1 gene or on a genealogical criterion - the presence of chronic pancreatitis in at least 2 first-degree relatives or at least 3 relatives in the second degree, in the absence of other identified predisposing factors (notably chronic alcohol consumption). It is now recommended to seek PH in cases of pancreatitis of unknown origin in a young patient or with a family history. In this study, patients carrying a PRSS1 mutation will be identified from the patient lists of the three French genetics laboratories (Brest University Hospital, Cochin-Paris University Hospital, Lille University Hospital) carrying out PRSS1 gene analysis. Patients will be included by the doctors currently treating them. The aim of the study is to assess the incidence of pancreatic adenocarcinoma in the cohort and describe the natural history of hereditary pancreatitis linked to a mutation in PRSS1.
Trial Details
NCT Number NCT07413029
Lead Sponsor Assistance Publique - Hôpitaux de Paris
Conditions Hereditary Pancreatitis, PRSS1 Gene Mutation
Enrollment 800 participants
Start Date 2024-11-10
Primary Completion 2044-11-30 (estimated)
Study Completion 2044-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-02-17